|Over a week ago|
Definitive Healthcare launches Monocl ExpertInsight 2.0, ExpertGo mobile app » 08:3306/1406/14/22
Definitive Healthcare announced the general availability of Monocl ExpertInsight 2.0, the next generation of the company's expert identification product, and a new mobile app, Monocl ExpertGO. These new offerings give medical affairs professionals access to nearly 13 million expert profiles globally so they can more quickly identify and engage the right scientific experts to provide critical insights that can accelerate the drug development process. Monocl ExpertInsight 2.0 provides an optimized user experience that helps medical affairs teams increase productivity, streamline workflows and develop more informed medical strategies. Monocl ExpertInsight 2.0 equips medical affairs teams with: Live filters that provide an overview of scientific activity with real-time updates and filters by expert and/or therapeutic area; Advanced search functionality to identify experts more easily in specific disease areas; Dynamic key opinion leader mapping, which displays the location of experts in granular detail down to the city level; Existing clients will get access to these new features at no additional cost as part of their existing Monocl ExpertInsight subscription. The new ExpertGO mobile app gives field medical leaders and medical science liaisons access to the latest intelligence, scientific activity and collaborator insights on experts around the globe. The ability to access these insights when and where needed is particularly valuable for MSLs, most of whom spend the majority of their time outside of the office, where they are visiting with experts in person. ExpertGO will be available to download on Apple and Android devices in late June at no additional cost to existing ExpertInsight customers. As part of this latest release, Definitive Healthcare also added Brazilian expert data to the Monocl ExpertInsight database to help life sciences teams gain a deeper understanding of the South American market. The new data covers intelligence on Brazilian healthcare professionals' location and specialty, using claims data.
|Over a month ago|
Definitive Healthcare reports Q1 EPS (9c), consensus (3c) » 16:5705/0505/05/22
Reports Q1 revenue $50.1M…
Reports Q1 revenue $50.1M , consensus $48.6M.
Definitive Healthcare price target raised to $26 from $21 at Deutsche Bank » 07:0204/0504/05/22
Deutsche Bank analyst…
Deutsche Bank analyst George Hill raised the firm's price target on Definitive Healthcare to $26 from $21 and keeps a Hold rating on the shares. The analyst adjusted estimates to better reflect the Analytical Wizards acquisition and the step up in amortization resulting from the transaction.
|Over a quarter ago|
Definitive Healthcare assumed with a Neutral at Credit Suisse » 16:1003/3103/31/22
Credit Suisse analyst…
Credit Suisse analyst Jonathan Yong assumed coverage of Definitive Healthcare with a Neutral rating with an unchanged price target of $24.
Definitive Healthcare launches passport analytics suite » 08:4103/1603/16/22
Definitive Healthcare announced the general availability of the Passport Analytics Suite, a set of products that helps life science organizations develop, launch and commercialize products more efficiently by delivering data-agnostic analytics on-demand. The Passport Analytics Suite is powered by Analytical Wizards, the company acquired by Definitive Healthcare in February 2022. "We are excited to launch this suite of highly configurable and scalable analytics products built on top of the fabulous technology that we acquired with Analytical Wizards," said Jason Krantz, founder and CEO of Definitive Healthcare. "With these tools, clients can effectively assess and optimize brand performance and dial in the optimal promotional mix. The Passport Analytics Suite helps clients optimize the entire commercialization process, from early-stage business planning needs through post-launch performance acceleration." Comprised of two products - Passport Promotional Analytics and Passport Planning & Performance - the Passport Analytics Suite delivers commercial intelligence around product planning, product performance and marketing optimization. The suite combines a highly configurable front-end application environment with an automated, efficient and scalable back-end cloud platform. The Passport Analytics Suite enables life sciences organizations to establish an analytics on-demand environment at-scale. The suite can integrate internal sales and marketing data with third-party big data on claims, EMR and lab/diagnostics data, as well as publicly available datasets including CMS, clinicaltrials.gov, and CDC epidemiology.
Definitive Healthcare price target lowered to $23 from $26 at Barclays » 07:1202/2402/24/22
Barclays analyst Saket…
Barclays analyst Saket Kalia lowered the firm's price target on Definitive Healthcare to $23 from $26 and keeps an Equal Weight rating on the shares. The analyst estimates the company's fiscal 2022 revenue growth equates to 27%-30% organic growth, which is faster than expected, but notes that its margins are lower.
Definitive Healthcare price target lowered to $24 from $30 at Credit Suisse » 07:0502/2402/24/22
Credit Suisse analyst…
Credit Suisse analyst Jailendra Singh lowered the firm's price target on Definitive Healthcare to $24 from $30 following quarterly results. The analyst keeps a Neutral rating on the shares.
Definitive Healthcare upgraded to Buy from Hold at Canaccord » 06:5902/2402/24/22
Canaccord analyst David…
Canaccord analyst David Hynes upgraded Definitive Healthcare to Buy from Hold with a price target of $28, down from $46. The quarter, the company's guidance and the acquisition of Analytical Wizards were each "equally promising," said Hynes, who argues that Definitive is continuing its measured investment into a "model with proven and attractive unit economics," and that it should show steady margin improvement off of Q1 lows. He thinks it makes sense to "lean into balanced growth and profit stories," such as Definitive, in the current market environment, Hynes said.
Definitive Healthcare reports Q4 adjusted EPS 4c, consensus 4c » 17:5202/2302/23/22
Reports Q4 revenue…
Reports Q4 revenue $46.31M, consensus $44.78M. "2021 was a transformational year for Definitive Healthcare, and we ended the year with strong financial results that reflect the significant momentum that we have across all parts of our business," said Jason Krantz, CEO and Founder of Definitive Healthcare. "Our innovation flywheel continues to spin, as we expand our data set and deliver new analytics that address our customers' most pressing challenges. Whether it's our new Latitude Reporting product, or our recent acquisition of Analytical Wizards, we continue to deliver the commercial intelligence that our customers need to navigate and sell into the large and complex healthcare market."
Definitive Healthcare launches Latitude Discovery product » 08:4301/2501/25/22
Definitive Healthcare announced the availability of Latitude Discovery, a new product aimed at pre-commercial biopharma and medical device companies. With Latitude Discovery, users can quickly perform iterative analysis of real-world data to assess and size potential market opportunities associated with therapy development for granular patient cohorts. Latitude Discovery is purposefully designed to meet the needs of pre-commercial pharmaceutical, biotechnology and medical device companies who are looking to bring new treatments to market. With billions of commercial medical claims, Latitude Discovery users gain self-service access to the precise market intelligence they need when they need it as they advance through the lengthy commercialization process. Key capabilities of Latitude Discovery include: The ability to quickly create new patient cohorts for analysis and reporting using any combination of diagnosis or procedure with additional filters on patients and providers; Rapid real-time commercial intelligence visualizations on the size of addressable patient and provider populations, clinical volumes, demographics and payor mix; Customizable claims data report templates to understand all additional diagnoses and procedures associated with the target population.